News
AGIO
--
0.00%
--
BRIEF-Agios Pharmaceuticals Says CEO Jacqualyn Fouse's 2020 Total Compensation Was $7.6 Mln Versus $16.6 Mln In 2019
reuters.com · 2d ago
Relapsed Acute Myeloid Leukemia Drug Market Recent Trends, In-depth Analysis, Market Size Research Report Forecast up to 2027
Apr 08, 2021 (Market Insight Reports) -- The latest report as Relapsed Acute Myeloid Leukemia Drug Market acknowledges Size, Application Segment, Type,...
Market Insight Reports · 2d ago
8-K: AGIOS PHARMACEUTICALS, INC.
(EDGAR Online via COMTEX) -- false 0001439222 0001439222 2021-03-31 2021-03-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 4d ago
8-K: AGIOS PHARMACEUTICALS, INC.
(EDGAR Online via COMTEX) -- false 0001439222 0001439222 2021-03-31 2021-03-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 04/03 00:49
Agios to repurchase $345 million stock from Bristol-Myers
Using the proceeds from the sale of the oncology portfolio to Servier Pharmaceuticals, Agios Pharmaceuticals ([[AGIO]] +1.6%) announced an agreement to repurchase ~7.1M shares or ~10% of its outstanding common stock from
Seekingalpha · 04/01 18:13
Servier Completes Acquisition of Agios Pharmaceuticals' Oncology Business
and , /PRNewswire/ -- Servier, a global pharmaceutical company, today announced that it has successfully completed its acquisition of Agios Pharmaceuticals' commercial, clinical, and research-stage oncology portfolio for up to plus royalties. The acquisi...
PR Newswire - PRF · 04/01 11:00
Press Release: Agios Announces Closing of Oncology Business Sale to Servier
Dow Jones · 04/01 11:00
Lymphoma Treatment Market to be Led by Bayer AG and Novartis AG, sates Fortune Business Insights™
Mar 30, 2021 (The Expresswire) -- The global “lymphoma treatment market” size is predicted to reach USD 13.11 billion by 2026, exhibiting a CAGR of 8.3%...
The Express Wire · 03/30 14:20
Why Is Agios Pharmaceuticals (AGIO) Down 1.3% Since Last Earnings Report?
Zacks.com · 03/27 21:54
Why Is Agios Pharmaceuticals (AGIO) Down 1.3% Since Last Earnings Report?
Zacks.com · 03/27 15:31
Agios Shareholders Approve Divestment of Oncology Business to Servier
MT Newswires · 03/26 04:24
8-K: AGIOS PHARMACEUTICALS, INC.
(EDGAR Online via COMTEX) -- false 0001439222 0001439222 2021-03-25 2021-03-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 03/26 04:19
Agios shareholders approve oncology business sale to Servier Pharmaceuticals
Agios Pharmaceuticals (AGIO) received shareholders approval for the previously disclosed sale of its commercial, clinical and research-stage oncology portfolio to Servier Pharmaceuticals, an independent global pharmaceutical company.Almost 90% of the outst...
Seekingalpha · 03/25 20:14
BRIEF-Agios Shareholders Approve Sale Of Oncology Business To Servier
reuters.com · 03/25 20:07
Agios Hldrs Approve Sale of Oncology Business to Servier
Agios Hldrs Approve Sale of Oncology Business to Servier
Dow Jones · 03/25 20:04
Relapsed Acute Myeloid Leukemia Drug Market Analysis Size, Growth and ComparisonRegions, Types and Applications 2020 to 2027 By Ameco Research
pune, India, Wed, 24 Mar 2021 02:59:11 / Comserve Inc. / -- The global Relapsed Acute Myeloid Leukemia Drug market is segmented by company, region (country),...
Comserve · 03/24 07:01
Agios Sponsors Program Promoting Health Literacy for Patients with Sickle Cell Disease
GlobeNewswire · 03/18 12:00
Cholangiocarcinoma Pipeline Insight: Therapeutic analysis of 70+ pipeline therapies and 70+ pharmaceutical companies
Los Angeles, USA, Mar 16, 2021 (GLOBE NEWSWIRE via COMTEX) -- Los Angeles, USA, March 16, 2021 (GLOBE NEWSWIRE) -- Cholangiocarcinoma Pipeline Insight:...
GlobeNewswire · 03/17 01:20
Insider Trends: 90-Day Insider Buying Trend at Agios Pharmaceuticals Slowed with Sale of Shares
MT Newswires · 03/16 16:22
8-K: AGIOS PHARMACEUTICALS, INC.
Edgar Online - (EDK = 8-Ks/S1/S-4) · 03/15 21:13
Webull provides a variety of real-time AGIO stock news. You can receive the latest news about Agios through multiple platforms. This information may help you make smarter investment decisions.
About AGIO
Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.